ASCO’s “rock concert” moments came 17 years apart—in 2005 and 2022 DESTINY-04 results extend HER2-targeted therapy to a larger population in breast cancer

Amid funding cuts and firings, cancer groups seek relief from judges, in Congress—and in the court of public opinion

As NCI employees and others at HHS were receiving notices of termination, national cancer organizations called on Congress “to restore stability to NIH.”

February 21, 2025

Vol.51 No.07

By Claire Marie Porter, Jacquelyn Cobb and Paul Goldberg

In Brief

Charles Geyer named associate group chair of NRG Oncology

The NRG Oncology Group Chairs created the position of associate group chair and selected Charles E. Geyer to fill the position, effective immediately. He will serve alongside the three NRG Oncology group chairs, Quynh-Thu Le, Robert Mannel, and Norman Wolmark.

February 21, 2025

Vol.51 No.07

Black History Month Podcast The Directors

On a new podcast, VCU’s Winn and City of Hope’s Carpten discuss the mission—and the future—of cancer centers
The Cancer Letter’s new podcast offers insight into cancer policy in a landscape of uncertainty

Is the Community Outreach and Engagement mandate the next item on the chopping block as the Trump administration makes its mark on science policy? What about health disparities research?

ASCO to recognize 11 Special Awards recipients at the 2025 annual meeting

ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the society’s highest honors at the 2025 ASCO Annual Meeting.

February 07, 2025

Vol.51 No.05

Clinical Roundup

Genentech’s Itovebi demonstrated OS benefit in advanced breast cancer, phase III trial finds

Genentech announced positive topline results from the overall survival analysis of the phase III INAVO120 study investigating Itovebi (inavolisib) in combination with palbociclib (Ibrance) and fulvestrant for people with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, endocrine-resistant, locally advanced or metastatic breast cancer.

January 31, 2025

Vol.51 No.04

Drugs & Targets

FDA approves Enhertu as first HER2-directed therapy for breast cancer

FDA approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic hormone receptor-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by the FDA approved test, that has progressed on one or more endocrine therapies in the metastatic setting.

January 31, 2025

Vol.51 No.04

ASCO’s “rock concert” moments came 17 years apart—in 2005 and 2022

DESTINY-04 results extend HER2-targeted therapy to a larger population in breast cancer

YOU MAY BE INTERESTED IN

Amid funding cuts and firings, cancer groups seek relief from judges, in Congress—and in the court of public opinion

Charles Geyer named associate group chair of NRG Oncology

On a new podcast, VCU’s Winn and City of Hope’s Carpten discuss the mission—and the future—of cancer centers
The Cancer Letter’s new podcast offers insight into cancer policy in a landscape of uncertainty

ASCO to recognize 11 Special Awards recipients at the 2025 annual meeting

Genentech’s Itovebi demonstrated OS benefit in advanced breast cancer, phase III trial finds

FDA approves Enhertu as first HER2-directed therapy for breast cancer

Renew today!

Subscriber content

Never miss an issue!

Login

ASCO’s “rock concert” moments came 17 years apart—in 2005 and 2022

DESTINY-04 results extend HER2-targeted therapy to a larger population in breast cancer

YOU MAY BE INTERESTED IN

Amid funding cuts and firings, cancer groups seek relief from judges, in Congress—and in the court of public opinion

Charles Geyer named associate group chair of NRG Oncology

On a new podcast, VCU’s Winn and City of Hope’s Carpten discuss the mission—and the future—of cancer centersThe Cancer Letter’s new podcast offers insight into cancer policy in a landscape of uncertainty

ASCO to recognize 11 Special Awards recipients at the 2025 annual meeting

Genentech’s Itovebi demonstrated OS benefit in advanced breast cancer, phase III trial finds

FDA approves Enhertu as first HER2-directed therapy for breast cancer

Never miss an issue!

Login

On a new podcast, VCU’s Winn and City of Hope’s Carpten discuss the mission—and the future—of cancer centers
The Cancer Letter’s new podcast offers insight into cancer policy in a landscape of uncertainty